All In Biotech

Drug Trial Radar · NCT05645692

A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

A Phase II, Randomized, Multicenter, Open-Label, Controlled Study of Tobemstomig Alone or in Combination With Tiragolumab Versus Atezolizumab in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer Who Are Ineligible for Platinum-Containing Chemotherapy

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 204 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

204

Actual

Start

Apr 13, 2023

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Dec 9, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety of tobemstomig alone or in combination with tiragolumab compared with atezolizumab in participants with previously untreated, locally advanced or metastatic urothelial cancer (mUC) who are ineligible to receive a platinum containing chemotherapy.

Conditions

  • Urothelial Cancer

Interventions

  • AtezolizumabDrug

    Participants will receive 1200 mg IV atezolizumab Q3W.

  • TobemstomigDrug

    Participants will receive 600 mg IV tobemstomig Q3W.

  • TiragolumabDrug

    Participants will receive 600 mg IV tiragolumab Q3W.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and Severity of Adverse EventsTime frame: Up to approximately 30 months

Locations

56 sites in 15 countries. Site status is shown where the registry gives one.

  • Cleveland Clinic

    Cleveland, Ohio

  • MD Anderson Cancer Center

    Houston, Texas

  • Macquarie University Hospital

    Macquarie Park, New South Wales, Australia

  • Lyell McEwin Hospital

    Adelaide, South Australia, Australia

  • ICON Cancer Care Adelaide

    Kurralta Park, South Australia, Australia

  • Hospital Universitario Evangelico De Curitiba

    Curitiba, Paraná, Brazil

  • Hospital das Clinicas - UFRGS

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital de Amor Amazônia

    Porto Velho, Rondônia, Brazil

  • *X*CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia

    Santo André, São Paulo, Brazil

  • Hospital Alemao Oswaldo Cruz

    São Paulo, São Paulo, Brazil

  • Beijing Cancer Hospital

    Beijing, China

  • West China Hospital - Sichuan University

    Chengdu, China

  • Sun yat-sen University Cancer Center

    Guangzhou, China

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, China

  • Aarhus Universitetshospital

    Aarhus N, Denmark

  • Herlev Hospital

    Herlev, Denmark

  • Centre Leon Berard

    Lyon, France

  • Gustave Roussy

    Villejuif, France

  • Krankenhaus Martha-Maria Halle-Dölau, Klinik für Urologie

    Halle, Germany

  • Martini-Klinik am UKE GmbH

    Hamburg, Germany

  • Alexandras General Hospital of Athens

    Athens, Greece

  • Attikon University General Hospital

    Chaïdári, Greece

  • Theageneio Hospital

    Thessaloniki, Greece

  • A.O. Universitaria Ospedale Consorziale Policlinico Di Bari

    Bari, Apulia, Italy

  • Istituto Nazionale Tumori Irccs Fondazione G. Pascale

    Naples, Campania, Italy

  • Azienda Ospedaliero-Universitaria S.Orsola-Malpighi

    Bologna, Emilia-Romagna, Italy

  • IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola

    Meldola, Emilia-Romagna, Italy

  • Policlinico Universitario "Agostino Gemelli"

    Rome, Lazio, Italy

  • Irccs Ospedale San Raffaele

    Milan, Lombardy, Italy

  • Azienda Ospedaliera S. Maria - Terni

    Terni, Umbria, Italy

  • IRCCS Istituto Oncologico Veneto (IOV)

    Padova, Veneto, Italy

  • Health Pharma Professional Research

    Mexico City, Mexico CITY (federal District), Mexico

  • Szpital Wojewódzki im. Miko?aja Kopernika

    Koszalin, Poland

  • Szpital Uniwersytecki w Krakowie

    Krakow, Poland

  • Pratia Poznan

    Późna, Poland

  • Szpital Grochowski im. dr med. Rafa?a Masztaka Sp. z o.o.

    Warsaw, Poland

  • Seoul National University Bundang Hospital

    Gyeonggi-do, South Korea

  • Gachon University Gil Medical Center

    Incheon, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital, Yonsei University

    Seoul, South Korea

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.